Literature DB >> 22781223

Trends in mortality according to hepatitis C virus serostatus in the era of combination antiretroviral therapy.

Juan Berenguer1, Belén Alejos, Victoria Hernando, Pompeyo Viciana, Miguel Salavert, Ignacio Santos, Juan L Gómez-Sirvent, Francesc Vidal, Joaquín Portilla, Julia Del Amo.   

Abstract

OBJECTIVE: To study trends in overall deaths and cause-specific deaths stratified by hepatitis C virus (HCV) serostatus in a cohort of combination antiretroviral (cART)-naive HIV-infected patients in Spain.
METHODS: We analyzed data from 1997 to 2008 in two calendar periods: 1997-2003 and 2004-2008. Deaths were ascertained through cohort reporting and a cross-match with the Spanish National Death Index. We used Poisson regression to model mortality rates and risk factors.
RESULTS: We analyzed 5974 HIV-positive cART-naive patients: 2471 (1497 HCV positive) in the period 1997-2003, and 3503 (689 HCV positive) in the period 2004-2008. A total of 232 deaths (158 during the first period, and 74 during the second period) were detected during 19 416 person-years of follow-up; the death rate was 12.9 of 1000 person-years. Crude overall death rates [95% confidence interval (CI)] were 16.5 (14.2-19.1) in 1997-2003 and 8.5 (6.7-10.6) in 2004-2008. The incidence rate ratio (IRR) (95%CI) in 2004-2008 taking 1997-2003 as a reference was 0.51 (0.39-0.67). When we stratified by HCV serostatus, the overall death IRR (95% CI) taking 1997-2003 as reference was 0.52 (0.32-0.85) for HCV-negative patients and 1.27 (0.90-1.79) for HCV-positive patients. When we considered cause-specific deaths (liver-related, AIDS-related, and nonliver-related/non-AIDS-related), findings were similar to those for overall-deaths.
CONCLUSION: Taking the first years of the cART era as a reference, we observed a decrease in overall and cause-specific mortality. This decrease was only observed in HCV-negative patients.

Entities:  

Mesh:

Year:  2012        PMID: 22781223     DOI: 10.1097/QAD.0b013e3283574e94

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  22 in total

1.  Inflammatory cytokines and mortality in a cohort of HIV-infected adults with alcohol problems.

Authors:  Daniel Fuster; Debbie M Cheng; Emily K Quinn; Kaku A Armah; Richard Saitz; Matthew S Freiberg; Jeffrey H Samet; Judith I Tsui
Journal:  AIDS       Date:  2014-04-24       Impact factor: 4.177

2.  Chronic hepatitis C virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems.

Authors:  Daniel Fuster; Debbie M Cheng; Emily K Quinn; David Nunes; Richard Saitz; Jeffrey H Samet; Judith I Tsui
Journal:  Addiction       Date:  2013-10-24       Impact factor: 6.526

3.  Short Communication: Coronary Heart Disease Risk by Framingham Risk Score in Hepatitis C and HIV/Hepatitis C-Coinfected Persons.

Authors:  Kara W Chew; Debika Bhattacharya; Kathleen A McGinnis; Tamara B Horwich; Chi-Hong Tseng; Judith S Currier; Adeel A Butt
Journal:  AIDS Res Hum Retroviruses       Date:  2015-05-11       Impact factor: 2.205

4.  Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?

Authors:  Nadine Kronfli; Jim Young; Shouao Wang; Joseph Cox; Sharon Walmsley; Mark Hull; Curtis Cooper; Valerie Martel-Laferriere; Alexander Wong; Neora Pick; Marina B Klein
Journal:  Clin Infect Dis       Date:  2021-08-02       Impact factor: 9.079

5.  Darunavir and ritonavir total and unbound plasmatic concentrations in HIV-HCV-coinfected patients with hepatic cirrhosis compared to those in HIV-monoinfected patients.

Authors:  Adrian Curran; Ramon Martí; Rosa María López; Mercè Pérez; Manel Crespo; María Jesús Melià; Jordi Navarro; Joaquín Burgos; Vicenç Falcó; Inma Ocaña; Esteban Ribera
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

Review 6.  Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a "special population"?

Authors:  Drosos E Karageorgopoulos; Joanna Allen; Sanjay Bhagani
Journal:  World J Hepatol       Date:  2015-07-28

Review 7.  Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014.

Authors:  Cody A Chastain; Susanna Naggie
Journal:  Curr HIV/AIDS Rep       Date:  2013-12       Impact factor: 5.071

8.  Hepatitis C virus seroconversion among HIV-positive men who have sex with men with no history of injection drug use: Results from a clinical HIV cohort.

Authors:  Ann N Burchell; Sandra L Gardner; Tony Mazzulli; Michael Manno; Janet Raboud; Vanessa G Allen; Ahmed M Bayoumi; Rupert Kaul; Frank McGee; Peggy Millson; Robert S Remis; Wendy Wobeser; Curtis Cooper; Sean B Rourke
Journal:  Can J Infect Dis Med Microbiol       Date:  2015 Jan-Feb       Impact factor: 2.471

9.  All-cause mortality in the cohorts of the Spanish AIDS Research Network (RIS) compared with the general population: 1997-2010.

Authors:  Victoria Hernando; Belen Alejos; Susana Monge; Juan Berenguer; Lourdes Anta; David Vinuesa; Rosario Palacios; Roberto Muga; Santiago Moreno; Inma Jarrin
Journal:  BMC Infect Dis       Date:  2013-08-20       Impact factor: 3.090

10.  Prevalence and Risk Factors of HCV/HIV Co-Infection and HCV Genotype Distribution in North-Eastern Poland.

Authors:  Anna Grzeszczuk; Alicja Danuta Wandalowicz; Jerzy Jaroszewicz; Robert Flisiak
Journal:  Hepat Mon       Date:  2015-07-22       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.